Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare Conference By: TELA Bio, Inc. via GlobeNewswire November 16, 2023 at 07:00 AM EST MALVERN, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will participate in Piper Sandler’s 35th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 35th Annual Healthcare Conference at 11:00 am ET on November 30th, 2023. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com. Investor ContactGreg Chodaczek347-620-7010ir@telabio.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare Conference By: TELA Bio, Inc. via GlobeNewswire November 16, 2023 at 07:00 AM EST MALVERN, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will participate in Piper Sandler’s 35th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 35th Annual Healthcare Conference at 11:00 am ET on November 30th, 2023. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com. Investor ContactGreg Chodaczek347-620-7010ir@telabio.com
MALVERN, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will participate in Piper Sandler’s 35th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 35th Annual Healthcare Conference at 11:00 am ET on November 30th, 2023. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com. Investor ContactGreg Chodaczek347-620-7010ir@telabio.com